Competitive Clinical Research Grant
Supports research on how lebrikizumab affects post-inflammatory dyspigmentation in moderate to severe atopic dermatitis, measured by the PDCA-Derm™ scale.
Funder: Eli Lilly and Company
Due Dates: February 15, 2026
Funding Amounts: Financial support and/or provision of study drug; award size and duration vary by proposal.
Summary: Supports investigator-initiated research on lebrikizumab’s impact on post-inflammatory dyspigmentation in moderate to severe atopic dermatitis.
Key Information: Full proposals must be submitted by the posted deadline; grantees are responsible for study design and regulatory sponsorship.
Description
Eli Lilly and Company’s Competitive Clinical Research Grant program provides external researchers with the opportunity to receive funding and/or study drug supply for investigator-initiated studies aligned with specific Requests for Proposals (RFPs). The current RFP focuses on evaluating the impact of lebrikizumab on post-inflammatory dyspigmentation, as measured by the PDCA-Derm™ scale, in patients with moderate to severe atopic dermatitis. Proposals are reviewed by internal and potentially external scientific committees, and selected grantees are fully responsible for the design, conduct, and regulatory aspects of their studies.
